GSK Investigator-sponsored studies programme

GSK is redefining its supported studies (investigator sponsored studies and supportive collaborative studies) submission process to an annual Call for Proposal model in the area of Respiratory medicine, to enable us to review and respond to proposals in an accelerated and more effective manner; and select proposals that best advance science and patient care.

For this reason the submission window for Respiratory ISS will be closed as of 23rd October 2018 until May 2019. We will issue an update in Spring 2019 with information on the exact dates for the call, our areas of interest and when you will receive a response back from us.

We recognise the implication this may have on your plans and we thank you for your patience.
For any queries please reach out to your local Medical point of contact.

We are dedicated to improving the quality of human life by enabling people to do more, feel better and live longer. As part of this commitment, we recognise the valuable role that our support of investigator-sponsored studies (ISS) plays in fulfilling this mission. An investigator-sponsored study is a research effort where the sponsor of the work is an investigator, healthcare institution, or some form of medical network external to GSK and is seeking our support to conduct the work. This support can be in the form of product, funding, or a combination of both.

We only support ISS that have a legitimate scientific purpose. The decision to support a study proposal is based on the importance of the research objectives to medical science or patient care, the scientific rationale for the proposed methodology, and the ability of the study sponsor to deliver a high-quality ethical study. Please refer to the User guidance for more information on GSKs current areas of interest.

We do not support ISS in order to reward healthcare professionals for using, purchasing, recommending, or prescribing GSK products or to persuade them to do so by supporting the proposed research. GSK is not committed to provide support (product or funding) until the legal agreement has been signed by both parties.

GSK’s policy is that human subject research results be made public. Therefore, as a condition of support the sponsor must provide a Public Disclosure Plan (PDP) as requested in the submission form. This should include details around publications and postings to a worldwide public register for all human subject research.

Any failure by the sponsor to meet the public disclosure commitments as detailed in PDP and legal agreement will be taken into consideration when reviewing any subsequent proposals submitted by the sponsor and may result in a decision by GSK not to support the proposal.

In order to fully utilise this site, you must first register a profile. Once registered, you will be able to:

  1. Submit study proposals directly into GSK’s ISS system, which will facilitate more timely reviews and decisions
  2. Check on the status of both proposals and previously approved active studies
  3. Post and receive electronic documentation directly through the system
  4. Receive periodic prompts regarding key milestones and deliverables associated with your proposals or previously approved studies

User guidance

Notification on belimumab proposals:

New investigator study proposals, within our current areas of interest, may be submitted up to 31st of January 2019 and will be reviewed by the belimumab ISS Committee in the next review cycle in Q1-2019. Review decisions will be communicated by Q2-2019. Decisions will be made on the basis of legitimate scientific purpose and the ability of the investigator to deliver a high-quality, ethical study. Please click on this link if you would like to know more about it.

Submit your proposal

Notification to all users:

For more information on HIV/AIDS research by ViiV and ISS programme, please contact your ViiV Healthcare representative. For ALL ISS proposals to GSK Vaccines (including HIV disease), please follow GSK process in this website.

Browser Requirements

Click here to view browser requirements for this portal.

Tell us how we are doing!

Terms of use Accessibility Cookie policy Privacy
© 2001-2018 GlaxoSmithKline plc. All rights reserved. Registered in England and Wales No. 3888792.
Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.